HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases.
This report contains market size and forecasts of Prophylactic HIV Drug in global, including the following market information:
Global Prophylactic HIV Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Prophylactic HIV Drug Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Prophylactic HIV Drug companies in 2021 (%)
The global Prophylactic HIV Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Prophylactic HIV Drug include Gilead Sciences, Merck, Mylan, Cipla, Bristol-Myers Squibb and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Prophylactic HIV Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Prophylactic HIV Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Prophylactic HIV Drug Market Segment Percentages, by Type, 2021 (%)
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
Global Prophylactic HIV Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Prophylactic HIV Drug Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Prophylactic HIV Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Prophylactic HIV Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Prophylactic HIV Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Prophylactic HIV Drug revenues share in global market, 2021 (%)
Key companies Prophylactic HIV Drug sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Prophylactic HIV Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences
Merck
Mylan
Cipla
Bristol-Myers Squibb
Roche